Description
Product Characteristics: CD276, also known as B7-H3, was initially identified as a member of the B7 family of proteins through its homology with previously identified B7 Molecules (1). CD276 mRNA is widely expressed, but its protein expression is usually rather low (2). CD276 has been shown to play a role in both the costimulation as well as the coinhibition of T cell response (3). In a similar fashion, CD276 plays a critical role in the control of antitumor immune responses in some cases, while in others appears to mediate antitumor immunity (4). It thus joins other immune checkpoint proteins as a possible therapeutic target for at least a subset of cancers.
Target Information: The protein encoded by this gene belongs to the immunoglobulin superfamily, and thought to participate in the regulation of T-cell-mediated immune response. Studies show that while the transcript of this gene is ubiquitously expressed in normal tissues and solid tumors, the protein is preferentially expressed only in tumor tissues. Additionally, it was observed that the 3' UTR of this transcript contains a target site for miR29 microRNA, and there is an inverse correlation between the expression of this protein and miR29 levels, suggesting regulation of expression of this gene product by miR29. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011]